Method for the treatment of metabolic disorders
View Patent ↗Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
1. A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome and Type II Diabetes, comprising administering to the subject an amount of a biologically active agent effective to treat the condition, wherein the agent is a compound of the formula:
wherein
n is 0, 1 or 2;
R 1 is hydrogen or alkyl having from 1 to 3 carbon atoms;
R 15 is hydrogen or alkyl having from 1 to 3 carbon atoms;
R 9 is hydrogen, halo, hydroxy, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula CXVII by a ring carbon;
or a pharmaceutically acceptable salt of the compound.
2. The method of claim 1 , wherein the agent is administered orally.
3. The method of claim 1 , wherein the subject is a human.
4. The method of claim 3 , wherein the agent is administered in an amount from one milligram to four hundred milligrams per day.
5. The method of claim 1 , wherein the compound is 4-{3-[((4-Trifluoromethylbenzylamino)-carbonyl)-4-methoxy]phenyl}-4-oxobutyric acid.
6. The method of claim 1 , wherein the compound is 4-{3-[((2,6-Dimethylbenzylamino)-carbonyl)-4-methoxy]phenyl}-4-oxobutyric acid.
7. The method of claim 1 , further comprising administering to the subject an effective amount of a therapeutic agent selected from the group consisting of: metformin; glyburide; combined formulation of metformin and glyburide; atorvastatin; lovastatin; pravastatin; simvastatin; clofibrate; gemfibrozil, rosiglitazone; pioglitazone; acarbose; and repaglinide.